BeiGene
BGNE
#881
Rank
ยฃ17.79 B
Marketcap
ยฃ159.02
Share price
-0.65%
Change (1 day)
-2.38%
Change (1 year)
BeiGene is a Chinese pharmaceutical company engaged in the R&D, and commercialization of molecularly-targeted, and immuno-oncology drugs for the treatment of cancer.

P/E ratio for BeiGene (BGNE)

P/E ratio as of November 2024 (TTM): -12.3

According to BeiGene 's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -12.348. At the end of 2022 the company had a P/E ratio of -11.4.

P/E ratio history for BeiGene from 2016 to 2023

PE ratio at the end of each year

Year P/E ratio Change
2022-11.4-36.25%
2021-17.831%
2020-13.629.03%
2019-10.5-10.14%
2018-11.7-72.27%
2017-42.3412.24%
2016-8.26

P/E ratio for similar companies or competitors

Company P/E ratio P/E ratio differencediff. Country
-0.9953-91.94%๐Ÿ‡บ๐Ÿ‡ธ USA
-5.63-54.41%๐Ÿ‡บ๐Ÿ‡ธ USA

How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.